2016International Journal of Pharmacology and Clinical SciencesOpen access

Comparative Study of Atorvastatin and Rosuvastatin in Combination with Fenofibrate in mixed Hyperlipidemia

Rohit R. Dixit, Shankar Jagan

Open full text 7 citations

Abstract

International Journal of Pharmacology and Clinical Sciences,2016,5,1,25-31.DOI:10.5530/ijpcs.5.1.5Published:March 2016Type:Research ArticlesAuthors:Rohit Dixit, and Shankar Jagan Author(s) affiliations:Rohit Dixit1 and Shankar Jagan2 1Department of Pharmacology, Navodaya Medical College, INDIA. 2Medical Review Safety Physician, Accenture, Chennai, INDIA. Abstract:Aim: To compare the effects of Atorvastatin and Rosuvastatin in combination with fenofibrate in patients with mixed Hyperlipidemia. Materials and Methods: It was an open label, randomized, parallel group, comparative, prospective clinical study. A total of 70 subjects diagnosed with mixed hyperlipidemia were screened and were randomly allocated into two groups of thirty each. Initial readings of lipid levels like TC, TG, HDL, LDL and VLDL for both the groups were taken as baseline values. Then, Group I received Tab Atorvastatin 10 mg + Fenofibrate 160 mg and Group II received Tab Rosuvastatin 10 mg+ Fenofibrate 160 mg once a day at night for 12 weeks. Patients were assessed after 12 weeks and their Lipid profile was done. Results: Patients who received a combination of atorvastatin with fenofibrate had a reduction of Total cholesterol by 39%, Triglycerides by 47%, LDL-C by 50% and VLDL-C by 35% respectively. In group treated with combination of rosuvastatin with fenofibrate there was a decrease in TC by 54%, TGs by 58%, LDL-C by 52% and VLDL-C by 56% respectively. At the same time, HDL-C levels were increased by 14% in the group treated with rosuvastatin with fenofibrate as compared to atorvastatin with fenofibrate treated group which increased the HDL-C levels by 6%. Conclusion: Both the treatment regimens significantly decreased TC, TG, LDL‑C, VLDL‑C, but the reduction was more and statistically significant in Rosuvastatin and fenofibrate combination group when compared with atorvastatin and fenofibrate treated group at the end of 12 weeks. Keywords:Atherosclerosis, Cholesterol, Heart, Lipoprotein, StatinsView:PDF (464.7 KB) PDFClick here to download the PDF file. Images Study design

About this research paper

What this paper is about

International Journal of Pharmacology and Clinical Sciences,2016,5,1,25-31.DOI:10.5530/ijpcs.5.1.5Published:March 2016Type:Research ArticlesAuthors:Rohit Dixit, and Shankar Jagan Author(s) affiliations:Rohit Dixit1 and Shankar Jagan2 1Department of Pharmacology, Navodaya Medical College, INDIA. 2Medical Review Safety Physician, Accenture, Chennai, INDIA. Abstract:Aim: To compare the effects of Atorvastatin and Rosuvastatin in combination with fenofibrate in patients with mixed Hyperlipidemia. Materials and Methods: It was an open label, randomized, parallel group, comparative, prospective clinical study. A total of 70 subjects diagnosed with mixed hyperlipidemia were screened and were randomly allocated into two groups of thirty each. Initial readings of lipid levels like TC, TG, HDL, LDL and VLDL for both the groups were taken as baseline values. Then, Group I received Tab Atorvastatin 10 mg + Fenofibrate 160 mg and Group II received Tab Rosuvastatin 10 mg+ Fenofibrate 160 mg once a day at night for 12 weeks. Patients were assessed after 12 weeks and their Lipid profile was done. Results: Patients who received a combination of atorvastatin with fenofibrate had a reduction of Total cholesterol by 39%, Triglycerides by 47%, LDL-C by 50% and VLDL-C by 35% respectively. In group treated with combination of rosuvastatin with fenofibrate there was a decrease in TC by 54%, TGs by 58%, LDL-C by 52% and VLDL-C by 56% respectively. At the same time, HDL-C levels were increased by 14% in the group treated with rosuvastatin with fenofibrate as compared to atorvastatin with fenofibrate treated group which increased the HDL-C levels by 6%. Conclusion: Both the treatment regimens significantly decreased TC, TG, LDL‑C, VLDL‑C, but the reduction was more and statistically significant in Rosuvastatin and fenofibrate combination group when compared with atorvastatin and fenofibrate treated group at the end of 12 weeks. Keywords:Atherosclerosis, Cholesterol, Heart, Lipoprotein, StatinsView:PDF (464.7 KB) PDFClick here to download the PDF file. Images Study design

Why it matters

OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

International Journal of Pharmacology and Clinical Sciences,2016,5,1,25-31.DOI:10.5530/ijpcs.5.1.5Published:March 2016Type:Research ArticlesAuthors:Rohit Dixit, and Shankar Jagan Author(s) affiliations:Rohit Dixit1 and Shankar Jagan2 1Department of Pharmacology, Navodaya Medical College, INDIA. 2Medical Review Safety Physician, Accenture, Chennai, INDIA. Abstract:Aim: To compare the effects of Atorvastatin and Rosuvastatin in combination with fenofibrate in patients with mixed Hyperlipidemia. Materials and Methods: It was an open label, randomized, parallel group, comparative, prospective clinical study. A total of 70 subjects diagnosed with mixed hyperlipidemia were screened and were randomly allocated into two groups of thirty each. Initial readings of lipid levels like TC, TG, HDL, LDL and VLDL for both the groups were taken as baseline values. Then, Group I received Tab Atorvastatin 10 mg + Fenofibrate 160 mg and Group II received Tab Rosuvastatin 10 mg+ Fenofibrate 160 mg once a day at night for 12 weeks. Patients were assessed after 12 weeks and their Lipid profile was done. Results: Patients who received a combination of atorvastatin with fenofibrate had a reduction of Total cholesterol by 39%, Triglycerides by 47%, LDL-C by 50% and VLDL-C by 35% respectively. In group treated with combination of rosuvastatin with fenofibrate there was a decrease in TC by 54%, TGs by 58%, LDL-C by 52% and VLDL-C by 56% respectively. At the same time, HDL-C levels were increased by 14% in the group treated with rosuvastatin with fenofibrate as compared to atorvastatin with fenofibrate treated group which increased the HDL-C levels by 6%. Conclusion: Both the treatment regimens significantly decreased TC, TG, LDL‑C, VLDL‑C, but the reduction was more and statistically significant in Rosuvastatin and fenofibrate combination group when compared with atorvastatin and fenofibrate treated group at the end of 12 weeks. Keywords:Atherosclerosis, Cholesterol, Heart, Lipoprotein, StatinsView:PDF (464.7 KB) PDFClick here to download the PDF file. Images Study design

Key concepts: Fenofibrate, Rosuvastatin, Atorvastatin, Hyperlipidemia, Medicine, Internal medicine, Very low-density lipoprotein, Gastroenterology

Related papers

Back to paper searchBrowse research topicsOriginal source
Comparative Study of Atorvastatin and Rosuvastatin in Combination with Fenofibrate in mixed Hyperlipidemia — Research Paper | ScholarLens